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Abstract
At present, industries within the health and life science sector are moving towards one another resulting in new industries
such as the medical nutrition industry. Medical nutrition products are specific nutritional compositions for intervention in
disease progression and symptom alleviation. Industry convergence, described as the blurring of boundaries between
industries, plays a crucial role in the shaping of new markets and industries. Assuming that the medical nutrition industry
has emerged from the convergence between the food and pharma industries, it is crucial to research how and which
distinct industry domains have contributed to establish this relatively new industry. The first two stages of industry
convergence (knowledge diffusion and consolidation) are measured by means of patent analysis. First, the extent of
knowledge diffusion within the medical nutrition industry is graphed in a patent citation interrelations network.
Subsequently the consolidation based on technological convergence is determined by means of patent co-classification.
Furthermore, the medical nutrition core domain and technology interrelations are measured by means of a cross impact
analysis. This study proves that the medical nutrition industry is a result of food and pharma convergence. It is therefore
crucial for medical nutrition companies to effectively monitor technological developments within as well as across industry
boundaries. This study further reveals that although the medical nutrition industry’s core technology domain is food,
technological development is mainly driven by pharmaceutical/pharmacological technologies Additionally, the results
indicate that the industry has surpassed the knowledge diffusion stage of convergence, and is currently in the consolidation
phase of industry convergence. Nevertheless, while the medical nutrition can be classified as an industry in an advanced
phase of convergence, one cannot predict that the pharma and food industry segments will completely converge or
whether the medical industry will become an individual successful industry.
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Introduction
The Health & Life Sciences sector is currently undergoing
significant change across all its industries. Boundary-crossing
developments are occurring, especially between the food and
pharmaceutical industries. The emergence of innovation at this
intersection is blurring the clear boundaries between these two
industries [1]. Such boundary-blurring innovation leads to
industry convergence, which in turn results in the emergence of
new industries. Food-pharma products resulting from this conver-
gence are known as Nutritional Supplements (NS), Functional
Foods (FF), and Medical Nutrition (MN). NS include vitamins,
minerals, herbs, amino acids, and other related products intended
to supplement the nutritional content of the diet in tablet/capsule
dosage [2]. FF are conventional foods with added nutrients that
claim to improve health beyond the basic nutritional functions [3–
8]. MN products are specific nutritional compositions for disease
intervention that effectively contribute to the therapeutic regimen
by improving a patient’s general condition [9,10]. MN can be
divided into tube feeding and oral nutritional supplements (e.g.
Nutridrink; Ensure; and Resource) and are primarily prescribed by
healthcare professionals. NS, FF, and MN are food substances that
are considered to improve health, and exist between conventional
foods and pharmaceuticals at the so-called food-pharma interface
(Figure 1) [11]. Nevertheless, the individual pharmaceutical and
food companies recognize the risks in developing food-pharma
inventions[10,12]. They fear that the commercialization of
boundary-spanning products [7] could result in a lower customer
acceptance due to the ambiguous identity of the product [7].
The present study focuses on the emerging MN industry, where
industry boundaries are still relatively undefined. This is reflected
by the terminology used to describe this product category, which is
most often perceived as confusing. MN is just one term among
many others to indicate the same product category (e.g. oral
nutritional supplement, medical food, clinical nutrition, enteral
nutrition).
The European (EU) MN industry comprises 5 leading
companies and currently finds itself in the growth phase of the
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industry lifecycle [7,13]. It is difficult to predict the prerequisites
for determining the future success of an emerging industry such as
the MN industry, nonetheless: carefully categorizing industries and
identifying industry boundaries is crucial and can lead to better
consumer perception and higher market acceptance [7,14–18]. In
the view that millions of patients are suffering from disease-related
malnutrition, including a surprisingly high proportion living in the
developed countries/high income economies [7,10,19] and many
studies have proven that nutritional interventions prevent and/or
support the development of disease-related malnutrition [10,19],
MN is considered of high societal value. Therefore, defining
industry boundaries may also have an indirect societal impact.
The first step in identifying industry boundaries is by determining
the status of industry convergence and thereby investigating how
and which distinct industry domains have contributed to establish
an industry.
In this research the concept of MN industrial convergence is
based upon the assumption that the phenomenon of industry
convergence proceeds along an evolutionary trajectory consisting
of four phases: Initialization; Knowledge Diffusion; Consolidation;
and Maturation (Figure 2) [20–22]. Such industry convergence has
been observed in many industries such as telecommunications,
computing and consumer electronics or cosmetics and pharma-
ceuticals [23–26]. In the initial stage, R&D of two or more distinct
industries segments remains independent. It is during the
knowledge diffusion stage where cross-disciplinary citations may
eventually result into joint research collaborations (consolidation
stage). As the metaphorical distance between the two knowledge
areas decreases, technology development follows, which in turn
leads to technology convergence [22]. It is believed that market
convergence is also a consequence of the new technological
combinations. Ultimately, sectors begin to merge with one
another, completing the industrial convergence process.
This study shows how and which distinct industry domains have
contributed to establish the MN industry. First we determine the
extent of knowledge diffusion within the MN industry, subse-
quently we define the consolidation into the MN industry on the
basis of technological convergence (Fig. 2), and eventually we
identify the MN core domains and chart the technology
interrelation and its influence on the MN industry development.
Both knowledge diffusion and technological convergence are two
important drivers of innovation and recognized as crucial
components for industry growth [26,27]. Specifically within the
health and life science sector, both drivers contribute to the
evolution of young and emerging industries such as the MN
industry [28]. Moreover, scientific advancements are the key
ingredient in stimulating both knowledge diffusion and techno-
logical convergence. The former - knowledge diffusion - is defined
as the process through which knowledge is spread along a specific
path in a social system [29]. Technological convergence implies a
technological change where inventions emerge at the intersection
of established and clearly defined industry boundaries [30]. The
cumulative effect of both drivers ultimately leads to industry
convergence [31].
The quantitative diffusion and consolidation results from this
study will contribute to detailed insights in MN industry
development and can help industry players to address specific
innovation strategies for the future.
Patents have been proven to be a valuable source of information
in mapping MN industry development [32,33], they contain about
80% of all technological knowledge and are generally regarded as
precursors of technological developments [22,34]. In addition,
they can be independently accessed and analyzed through various
types of comprehensive and open databases [35]. Finally, in
contrary to other knowledge sources, such as scientific literature,
patents are categorized according to multiple technology classes
according to their technological characteristics. This allows for
accurate co-classification analyses to identify the interrelation
between technologies [36]. Therefore, in this study, patent data
was used to identify the evolutionary (technological) development
of the MN industry.
Methodology
The methods applied in this study are based on research
methods by Karvonen, Tseng, and Choi [30,37,38] and adapted
to fit our research objective. To determine the stage of
convergence in the MN industry, this study is divided into
Knowledge Diffusion and Consolidation. Furthermore, the
consolidation is divided into technological convergence, and CIA
(Figure 3). Data on patents concerning MN was extracted from the
Derwent Innovations IndexSM and Espacenet pertaining to the
European published patent applications. In total, 274 patent
applications were filed by the 5 leading EU MN companies from
1984 up to 2013 (so called; main patents).
Knowledge diffusion
Since knowledge convergence is the first stage of convergence,
the analysis of knowledge flow within the MN industry is an
appropriate method for identifying possible current and future
convergence between knowledge disciplines originating from
different industries [39]. Patent citation data is considered an
important information source for analyzing science-based knowl-
edge flows. Patent citations within the MN industry are indicative
for the technological relationship between patents in the MN
industry [40–44]. Patent citations refer to the number of cited
patents within the original patent application as an indicator of
prior art. Such an analysis provides information of inter- industry
competition and knowledge spillovers [30,45].
In order to identify the knowledge diffusion within the MN
industry, the backward citations of all main patents were extracted.
Subsequently, we constructed an affiliation network visualizing the
interrelations of all main patents of the European MN companies.
This method is a powerful tool to analyze knowledge flows and
within-industry competition [37]. The mutual linkage between the
main MN patents were explored and visualized using the statistical
software programs Ucinet and NetDraw [46]. This network
represents the knowledge flows between the European MN
Figure 1. Industries situated at the food-pharma interface.
Adapted from [7].
doi:10.1371/journal.pone.0082609.g001
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Figure 2. Linear model of convergence adapted from [20–22,65].
doi:10.1371/journal.pone.0082609.g002
Figure 3. Research framework.
doi:10.1371/journal.pone.0082609.g003
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companies (anonymous) and gives an indication of within industry
competition.
Technological convergence
In general, patents have multiple technology classifications
depending on their claims. Since patents are classified into certain
technological classes according to their technological characteris-
tics, co-classification analysis identifies the interrelation between
technologies [36]. The co-classification analysis measures the
frequency by which two classification codes are jointly assigned to
a patent and can be interpreted as an indication of the strength of
the technological relationships. Ultimately, this allows for calcu-
lating technological convergence [35,47]. The co-classification in
this study is based on the Cooperative Patent Classification (CPC)
codes [48]. Since the MN industry is not yet assigned to one
specific classification category, the co-classification of different
technologies currently delineates this industry. This is in accor-
dance with the fact that the MN industry is still in growth phase as
described earlier [7].
The expert designated CPC codes from each patent were
extracted to analyze science-based technological convergence
within the MN industry. CPC is an extension of the International
Patent Classification (IPC) and is a joint endeavor of the European
Patent Office (EPO) and the United States Patent and Trademark
Office (USPTO) to harmonize the classification systems into a
single system. This jointly developed classification system is much
more granulated than the IPC system.
The CPCs were extracted from the patent search and analysis
software ACCLAIMiP and the Espacenet portal. Since patents
can be classified into several CPC groups, the co-classification
provides information concerning technological convergence. In
order to reveal the technological convergence domains within the
MN industry, the first two (converging) CPC codes were extracted
from all main patents and grouped into various domain
combinations [30,49,50]. CPC codes are a hierarchical way of
assigning the category to which every patent belongs [51]. The
MN patents are categorized into classes, which are divided into
sub-classes, main groups and sub-groups. The main groups are
merged into domain combinations as illustrated in Table 1. In this
study we make no difference between the orders of category
combinations (e.g. no difference between 1–2 and 2–1). Subse-
quently, the number of patents per domain combination was
divided in time blocks of 5 years, showing the evolutionary
development of the emerging MN industry.
There is a predicted lag in the convergent domains since patent
applications are available in the public domain only 18 months
after filing. As a result, the dataset is accurate to Jan 2012 and
therefore by definition no 2013 patent applications could be
included.
Cross impact analysis
The identification of the overall structure of technologies and
interaction among them is essential to recognize the maturity of
technological trends and discover technological possibilities
through convergence between various fields of technologies [52].
Cross Impact Analysis (CIA) is considered a reliable quantitative
methodology to identify the core technologies and interrelations
between technology domains [53–55] based on patent classifica-
tion data [38]. In our study, the technology impact between
various MN technology domains is analyzed based on patent co-
classification data as described in technological convergence
section. The impact between technologies can be derived from
the CPC codes of the patent. Moreover, the impact of (A, B) can
be defined as conditional probabilities between two technologies
[38]. This means that the cross impact of technology A on
technology B can be defined as follows: Impact (A, B) = P (B|A) = (N
(A > B))/(N (A))
In this equation, N (A) refers to the total number of patents
included in domain A, and N (A>B) indicates the number of
patents, which include both domain A and domain B. The patent-
based cross impact between domains can be analyzed by
calculating the conditional probability with the number of patents
in the patent classes. The score of index ranges from 0 to 1. If the
score is close to 1, then technology domain A has a high impact on
technology domain B and when the score is approaching the 0, the
impact is considered lower.
Technology pairs based on the cross impact scores can be
classified into three groups. In case 1, the so-called bidirectional
impact, most of the patents in technologies A and B overlap;
hence, both Impact (A, B) and Impact (B, A) are high.
Consequently, conditional probabilities are relatively high and
the impacts of one technology on the other technology are both
high.
In case 2, called one directional impact, a high number of
patents in technology A is also included in technology B, however,
the portion of patents in technology B that is also included in
technology A is relatively small. This means that Impact (A, B) is
high, but Impact (B, A) is low. In this case, the impact between
technologies A and B is unidirectional.
In case 3, called nonimpact, technologies A and B are almost
exclusive and there is little interaction between them. Basically,
these two technologies can be said to be almost independent.
Moreover, the individual impacts between the domains are
visualized by means of network analysis depicting the type of
interaction (arrow) between the domains (node). The direction of
the arrow indicates the direction of impact between two domains.
It visualizes whether technologies are equally influencing one
another (bidirectional) or whether the impact of the first
technology on the second is different from the impact of the
second technology on the first (unidirectional) [38,56].
Patent data is a valuable source of information and is useful in
the study of technological convergence and diffusion as well as in
technology interrelation and development. Nonetheless, not all
inventions are patented and changes in patent law over the years
make it difficult to analyze trends over time [57]. Since the
protection afforded to patentees worldwide has been improved,
the companies are more inclined to file for a patent than before
[57]. Additionally, since CPC is a joint endeavor of the EPO and
USPTO, this classification system is more detailed, up to date, and
dynamic [51]. Subsequently, we have applied the quantitative
patent-based CIA method of Choi [38] as opposed to the more
conventional qualitative (CIA) approach, by means of literature
surveys and expert interviews, aiming to overcome inconsistent
outcomes. Furthermore, the citations lag between the application
or grant year of the citing patent and that of the cited patents make
it impossible to assemble all the main patents within the MN
industry up until present time [58]. To address this limitation, a
prediction line was drawn (result section CIA).
Results
In total, 274 patent applications were filed by the 5 leading
European MN companies between 1984 and 2013. The MN
patents can be assigned to 5 classes which are subsequently divided
into 7 sub-classes , 37 main groups ,and 151 sub-groups.
Food-Pharma Convergence in Medical Nutrition
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Knowledge Diffusion
The knowledge diffusion network shows that most patents (78%)
are not interrelated within the MN industry by means of patent
citations. Interestingly, figure 4 shows that the remaining 22% of
the patents lead back to two patent precursors and the CPCs of the
precursors indicate convergence between the Food – Food
Compositions and the Food – Pharmaceutical Organic Active Ingredients
industrial domain combinations (Figure 4). The remaining 78% of
the main patents are not linked to patents within the MN industry
domain and are therefore linked to patents from other industrial
domains. The high occurrence of patent linkage beyond the
industrial domain indicates boundary-spanning convergence is
taking place in MN development.
Technological convergence
Figure 5 illustrates that between 1989 and 2013, 84% of all MN
main patents show convergence between different industrial
domains indicating technological convergence. Furthermore,
figure 5 demonstrates that convergence of industry domains have
played an essential role in the MN industry development since
1989, nevertheless, the importance of specific domain combina-
tions varies over the course of time (Figure 6).
Further sub-categorization of the MN domains, indicating
domain convergence, reveals the 5 most prevalent sub-groups:
Food – Medicinal preparations containing organic active ingredi-
ents; Food – Medicinal preparations containing peptides; Food –
Food Compositions; Food – Medicinal preparations containing
Table 1. Predominant CPC groups in MN patent literature.
Nr. CPC Code Groups
1 A23K1 Animal feeding-stuffs
2 A23G1 Cocoa; Cocoa products
3 A23F5 Coffee; Coffee substitutes; Preparations thereof
4 A61K8 Cosmetic or similar toilet preparations
5 F24D19 Details
6 A23D7 Edible oil or fat compositions containing an aqueous phase
7 Y02B30 Energy efficient heating, ventilation or air conditioning
8 A61J15 Feeding-tubes for therapeutic purposes
9 A23V2002 Food compositions, function of food ingredients or processes for food or foodstuffs
10 A23L1 Foods or foodstuffs
11 C07K16 Immunoglobulins
12 A61K9 Medicinal preparations characterized by special physical form
13 A61K45 Medicinal preparations containing active ingredients
14 A61K2039 Medicinal preparations containing antigens or antibodies
15 A61K33 Medicinal preparations containing inorganic active ingredients
16 A61K35 Medicinal preparations containing materials or reaction products thereof with undetermined constitution
17 A61K31 Medicinal preparations containing organic active ingredients
18 A61K38 Medicinal preparations containing peptides
19 A61K36 Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof
20 A23C9 Milk preparations; Milk powder or milk powder preparations
21 A23C11 Milk substitutes
22 A61K2300 Mixtures or combinations of active ingredients
23 A23L2 Non-alcoholic beverages; Dry compositions or concentrates therefor
24 A23J1 Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
25 A23D9 Other edible oils or fats
26 C07K14 Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
27 A23J7 Phosphatide compositions for foodstuffs
28 C12P19 Preparation of compounds containing saccharide radicals
29 C12P17 Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
30 A61Q19 Preparations for care of the skin
31 A23L3 Preservation of foods or foodstuffs, in general
32 C12R1 Processes using micro-organisms
33 A23G3 Sweetmeats; Confectionery; Marzipan; Coated or filled products
34 A23F3 Tea; Tea substitutes; Preparations thereof
35 A23C21 Whey; Whey preparations
36 A23J3 Working-up of proteins for foodstuffs
doi:10.1371/journal.pone.0082609.t001
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combinations of active ingredients (MPOAI); and Food –
Materials/Reaction Products (Figure 6).
Figure 6 shows that from 1989 until now Organic Active
Ingredients, Food Compositions, and Peptide Compositions have
played an essential role in the development of MN industry. In
1994 a new domain combination emerged: Food – Materials/
Reaction Product. Since 1999, another new domain combination
emerged: Food – Medicinal preparations containing peptides.
The principal domain convergence has occurred between the
Food domain and MPOAI domain. Examples of MPOAI are:
Figure 4. Knowledge diffusion within the MN industry - Network of the main patents (coded company, patent number - application
year). Visualization presents the backward citing between main patents of MN companies. This network visualizes those patents that are linked.
Symbols indicate the 5 MN companies; The direction of the arrow indicates the cited patent.
doi:10.1371/journal.pone.0082609.g004
Figure 5. Evolution of single domains versus different domain convergence in MN – MN cannot be classified as a single domain but
predominantly as a convergence between different domains.
doi:10.1371/journal.pone.0082609.g005
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carbohydrates; sugars; carboxylic acids; hydrocarbons; amino
acids; vitamins; and medicinal plant derivatives.
CIA
The cross impact scores help classify each technology pair into
three groups: Bidirectional, Unidirectional, and Non-impact. The
CIA network illustrates that 22 out of 47 technology pairs can be
classified as bidirectional- or unidirectional impact (Figure 7).
Furthermore, the bottom-right quadrant of figure 7 illustrates a
network graph of the relationships between technology domains
within the MN industry. Each node represents a technology
domain and the color of the node indicates its corresponding score
that classifies the impact between two technology domains. The
bidirectional impact technology pairs are expressed as blue nodes
and the unidirectional impact technology pairs as red nodes.
Furthermore, the direction of the arrows indicates the direction of
impact. The network graph helps us identify the influencing- and
influenced technology domains.
The network graph indicates that 11 technology domains
directly influence the food domain. Eight of the eleven influencing
domains originate from food (8, 9, 20, 23, 28, 31, 35 and 39) whilst
three domains (15,16 and 17) originate from pharma. The
domains impacting the food domain (10) that originate from
pharma account for 138 patents, while the domains originating
from food account for 57 patents.
The central positioning of Food (10) in the network graph shows
that this technology domain can be considered as the core MN
domain. Additionally, technological development from the phar-
maceutical domain, especially medicinal preparations containing:
inorganic active ingredients, organic active ingredients and
materials or reaction products thereof with undetermined consti-
tution, influence the core MN domain.
Discussion and Implications
This study proves that the MN industry is a result of a bona fide
food-pharma convergence. Additionally, the results indicate that
the industry has surpassed the knowledge diffusion stage of
convergence, and is currently in the consolidation phase of
industry convergence. Nevertheless, while the medical nutrition
can be classified as an industry in an advanced phase of
convergence, one cannot predict that the pharma and food
industry segments will completely converge or whether the MN
industry will reach a state of maturation and become an individual
successful industry. This confirms previous research which
revealed the MN industry to be in the relatively early development
stage of the technology life cycle [9]. The knowledge flows and
subsequently trans-disciplinary technological convergence between
the food-pharma technology domains have fine-tuned the MN
industry as it is today. This study further reveals that although the
MN industry’s core technology domain is food, the technological
development is mainly driven by pharmaceutical technologies.
Although not scientifically proven, in the past few years
literature has stated that the gap between pharmacology and
nutrition science has been narrowing, a development stimulated
by both disciplines [10]. The increase in technological conver-
gence between food and MPOAI confirms this observation, which
Figure 6. Food-Pharma dominates the domain convergence in MN - Selection of top 5 converging domains from 1989 up to 2013 in
MN.
doi:10.1371/journal.pone.0082609.g006
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previously has been termed as ‘‘pharmaconutrition’’. Although in
the past only drugs were considered pharmacologically active
substances, this new treatment paradigm embraces the fact that
nutrients can have profound effects on immunological, metabolic
and other pathophysiological processes of diseased patients
[10,59].
Our results show that there are currently five different CPC
combinations required to define MN in patent literature. This
emphasizes the necessity for a specific CPC code to clearly
categorize MN, which may contribute to clearly delineating MN
industry boundaries. Having its own identity may lead to better
consumer perception and higher market acceptance thereby
stimulating MN market growth.
Considering that convergence drastically alters industry struc-
tures, companies should consider evaluating whether their
activities may be affected by trends of convergence [60]. By
monitoring convergence trends, companies can benefit by
commercializing on trans-disciplinary opportunities. The MN
industry can be characterized as a convergent/converging area at
the food-pharma interface and it is therefore crucial for MN
companies to effectively monitor developments within as well as
across industry boundaries. Both in the food- and pharmaceutical
industry trends should be monitored, as our results indicate that
critical knowledge is also developed in those fields [60]. Especially
the technological development within the pharmaceutical industry
is essential since our CIA results shows that pharmaceutical
technologies have the greatest impact on MN development.
The knowledge diffusion results indicate a high occurrence of
patent linkage beyond the MN industrial domain implying that the
first step in boundary-spanning industry convergence: knowledge
diffusion, is taking place in MN development. Our empirical
analysis further reveals both knowledge and technological
convergence between the food-pharma technological domains,
thereby showing the first three phases of convergence of the linear
model of convergence in the MN industry.
Nevertheless, it is often argued that factors other than
technology are involved in the process of industry convergence.
Weaver (2007) and Karvonen & Kassi (2013) believe that
technology and industry convergence are often intrinsically linked,
yet these two concepts are causally and conceptually distinct
[30,61]. Examples of those factors include: regulation, quality
standards, business model innovation, changing customer require-
ments and industry channel structure. The process of food-pharma
convergence is nurtured by the trend of regulatory convergence
with respect to costly clinical research increasingly required for
MN. These factors can be divided into supply (science, technology)
and demand (consumer needs) factors.
The absence of competencies in either supply or demand
understanding may lead to considerable problems at the front end
of innovation (idea generation, evaluation and selection) [26]. Our
Figure 7. Grouping of the technology pairs in the MN industry, Network graph of bidirectional and unidirectional impact within the
MN industry (1984–2013).
doi:10.1371/journal.pone.0082609.g007
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Figure 8. Front end of innovation activities in converging industries. Adapted from [26].
doi:10.1371/journal.pone.0082609.g008
Figure 9. Categorization of MN industry convergence, adapted from [64].
doi:10.1371/journal.pone.0082609.g009
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results indicate that the front end of MN innovation is affected by
convergence (Figure 8). Especially as the process of innovation
requires the combination of new knowledge and competencies
owned by different industries domains [26]. Perhaps this is one of
the reasons that the MN industry may currently be facing an
innovation cliff [7,9,62]. We would argue that in the MN industry,
front-end innovation challenges are related to the converging
industries. For example; the food industry counterparts of the
trans-disciplinary venture might experience challenges on the
technological/supply aspect of the convergence (e.g. clinical trials
(endpoints, quality standards, pharmacokinetics and pharmacody-
namics [10]) whereas the pharmaceutical participant may find the
consumer/demand experience (e.g. taste, texture, tolerance, smell)
a particular bottleneck (Figure 8). Successful convergence would
therefore require awareness on matching skills, experience and
resources that would complement the, otherwise lacking, absorp-
tive capacity [26]. Innovation managers must be aware of
competence gaps on the supply and/or demand side. One way
to bridge this gap is to identify external partners, already at the
idea generation phase, with the additional competences to account
for the missing absorptive capacity [26]. Such innovation strategies
by means of acquisition and consolidation are already occurring in
the MN industry and may contribute to progressing to the final
stage of convergence: maturation [7].
We argue that the result of food-pharma convergence into the
MN industry is both supply (technology) and demand (consumer)
driven. For example, technology has made it possible to reduce the
volume of high-protein oral nutritional supplements (ONS) while
simultaneously, due to a higher awareness of MN effectiveness, the
demand for low-volume high-protein ONS is rising. Due to
convergence of the supply (pharma) and demand (food) sides, a
new MN value chain emerges. Value chain reconfiguration as a
result of industry convergence may lead to the elimination of entire
value chain steps or activities while other, value-added value chain
activities may be introduced [61,63].
In addition to diagnosing the MN industry to be in stage three
of the industry convergence life cycle, the process of convergence
in itself comes in two varieties; substitutive and complementary.
Such a classification allows for characterization of the convergent
industry. In the case of substitutive convergence, innovation leads
to a phasing out of the two formerly discrete operating industries.
Consequently; the added value of the complementary products
combined is higher when compared to the individual components,
thereby resulting in technological substitution from a consumer
perspective (1+1= 1). Complementary convergence is the process
whereby previously unrelated products are bundled together to
form a new combined and integrated class of product with added
value for end-users (1+1= 3) [61,63]. In this case, the convergence
between technologies results from technology fusion or by
bundling exemplify complementarities [64]. The MN industry
belongs to the second category in the view that MN replaces
neither conventional foods nor pharmaceutical products (Figure
9).
Ultimately, additional research is required to understand the full
impact of the MN industry within the context of the individual
food and pharmaceutical industries. While this study focused on
the use of patents to identify the stages of industry convergence,
future research could focus on complementary data and methods
for mapping the convergence process. One option may be to look
at clinical research data by assessing to what extent these studies
meet pharma industry standards. The MN industry offers a unique
dataset for studying industry convergence and experimenting with
tools on how this is best accomplished.
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